![Caileigh Dougherty](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Caileigh Dougherty is currently Head-Investor Relations & Media at TScan Therapeutics, Inc. Former roles include Director-Investor Relations at Athenex, Inc. and Head-Investor Relations at Intercept Pharmaceuticals, Inc.
| Empresas | Cargo | Inicio |
|---|---|---|
| TSCAN THERAPEUTICS, INC. | Contacto de Relaciones con Inversores | 01/12/2025 |
| Empresas | Cargo | Fin |
|---|---|---|
| ATHENEXPAR | Public Communications Contact | 01/09/2022 |
| INTERCEPT PHARMACEUTICALS, INC. | Public Communications Contact | 01/08/2021 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
Athenex, Inc.
 Athenex, Inc. BiotechnologyHealth Technology Develops and commercializes drugs for cancer and immunomodulatory diseases | Health Technology |
Intercept Pharmaceuticals, Inc.
 Intercept Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of chronic fibrotic and metabolic diseases | Health Technology |
TScan Therapeutics, Inc.
 TScan Therapeutics, Inc. BiotechnologyHealth Technology Develops T-cell therapies for cancer patients | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
